Carrier screening helps identify couples who carry certain genetic mutations that could cause serious genetic disorders in their offspring. It analyzes a few genes at a time to look for variants associated with disorders like cystic fibrosis, fragile X syndrome, spinal muscular atrophy, and Tay-Sachs disease. Identifying carriers through screening assists in reproductive decision-making.

The rise of non-invasive prenatal testing (NIPT) is a key trend driving growth of the carrier screening market. NIPT uses cell-free DNA analysis of maternal blood to screen for chromosomal abnormalities with a high degree of accuracy. It has emerged as a first-tier screening option and has largely replaced conventional screening methods like ultrasound measurements and serum biomarkers. NIPT also enables carrier screening, allowing couples to know if they are carriers for genetic disorders like cystic fibrosis and spinal muscular atrophy. This has boosted adoption of carrier screening significantly.

The global carrier screening market is expected to witness high growth, exhibiting CAGR of 17% over the forecast period, due to increasing awareness about genetic diseases and availability of expanded carrier screening panels.

The North American region currently dominates the carrier screening market due to favorable reimbursement policies and regional presence of leading market players. Asia Pacific is projected to witness fastest growth during the forecast period driven by rising healthcare expenditure and patient population base.

Key players operating in the carrier screening market are Myriad Genetics, Inc; Cepheid; Illumina; Thermo Fisher Scientific Inc.; F.Hoffmann-La Roche Ltd; Laboratory Corporation of America Holdings; Otogenetics ; MedGenome; GeneTech ; and Centogene N.V. Market players are focusing on collaborations, new product launches, and geographic expansion to strengthen their market presence.

Read More

https://healthcarelatesteditionnews.blogspot.com/2023/11/artificial-intallegence-is-fastest.html